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A b s t r a c t  
Colchicine has been reported to play important roles in hepatoprotection, anti-inflammation in vitro 
anti cancer activity. The present study was initiated to evaluate antioxidant and anti-cancer effects of 
colchicine (10øg/mice, i.p.) in mice after subcutaneous implantation of ehrlich ascites carcinoma 
(EAC) for 21 days. On the 22th day, the mice were sacrificed for the estimation of tumor growth, and 
biochemical parameters (glucose, insulin, alanine transaminase (ALT), aspartate transaminase 
(AST), alkaline phosphatase (ALP), lactate dehydrogenase (LDH), lipid peroxides (TBARS), protein 
thiols (Pr-SHs), reduced glutathione (GSH), superoxide dismutase (SOD), glutathione peroxidase 
(GPx), total cholesterol (TC), triglycerides (TG), HDL-C, LDL-C, 17β-estradiol and progesterone). 
The results of this study showed that administration of colchicine and 5-Flourouracil individually for 
21 days to the carcinoma induced mice demonstrated a significant (P<0.01) decrease in tumor 
weight and a significant (P<0.01) improvement in biochemical parameters and life span  compared 
to the EAC control mice. In addition, the results clearly suggest that colchicine induced antioxidant 
activity on experimental EAC control mice.   
Keywords: Colchicine, 5-Flourouracil, breast cancer, Ehrlich ascites cells and antioxidants.
Introduction  
Cancer is one of the most prevalent groups of disorders in the 
population in many countries worldwide (1). Cancer is a term 
describing conditions characterized by uncontrolled cellular 
proliferation and differentiation (2). Oxidative stress is involved in 
the process of development of cancer and tumors; due to reactive 
oxygen species (ROS) that can damage the macromolecules as 
lipids , react with metals (as free iron and copper) , produce 
aldehydes and synthesize malondialdehyde inducing mutations (3) 
or cause breaks in the double chain, produce modifications in 
guanine and thymine bases, and sister chromatid exchanges (4). 
The alkaloids represent the largest single class of plant secondary 
metabolites. They have a remarkable range of often dramatic 
pharmacological activity, and are also often toxic to man (5). Many 
alkaloids are used in therapeutics and as pharmacological tools. A 
wide range of biological effects has been reported for alkaloids, 
including antitumor and anti-inflammatory activities (6). Colchicine 
is an alkaloid drug, chemically known as N-[(7S)-1, 2, 3, 10-
tetramethoxy-9-oxo-5,6,7,9-tetrahydrobenzo[a] heptalen-7-yl] 
acetamide, and widely used for the treatment of gout disease (7).  
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Figure. 1: Structure of colchicines 
 
Colchicine has a high market value and consistent demand in the 
field of medicine (8). The alkaloid, colchicine is the drug of choice 
to relieve acute attack of gout, familial Mediterranean fever (9) and 
a cure for cancer related diseases (10, 11). Also, colchicine, a 
recognized liver protector which prevents the assembly of 
cytoplasmatic microtubules, inhibits the transcellular movement of 
collagen (12, 13), stimulates the production of collagenase in 
cultures of synovial tissue (14) and exerts a stabilizing effect on the 
plasma membranes of the hepatocyte (15). It prevents infiltration 
reverses CC14-induced liver cirrhosis in rats (16, 17).  
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Not surprisingly, alkaloid such as colchicine contains 4 methoxy 
groups are excellent scavengers of ROS and represent promising 
anti-tumor effects. In vivo tests have been conducted with 
colchicine to determine for example, its hepatoprotective (16), anti-
inflammatory (7) and in vitro anticancer activity (11). To our 
knowledge, there are no reports about in vivo antitumor activity of 
colchicine. The present study aimed to evaluate the antitumor 
activity of colchicine as well as compared to 5-Flourouracil in 
female albino mice.   
Materials and Methods 
Mice 
This experiment was conducted in accordance with guidelines 
established by the Animal Care and use Committee of October 6 
University. Adult mice weighing around 25 μ 2gms were purchased 
from Faculty of Veterinary Medicine, Cairo University. They were 
individually housed in cages in an air-conditioned room with a 
temperature of 22 μ 2oC, a relative humidity of 60%, and an 8:00 to 
20:00 light cycle. During the acclimatization period, each animal 
was raised on a regular diet ad-libitum. 
Chemicals 
5-fluorouracil and colchicine were obtained from Merck Ltd., 
Germany. All the other reagents used were of analytical grade and 
were obtained commercially. 
Experimental design 
EAC cells were obtained from the National Cancer Institute, Cairo 
University.  The cells maintained in vivo in Swiss albino mice by 
subcutaneous transplantation (2x106 cells per mouse) to the 
animals of all groups except the first group (18). 
The animals enrolled in the present study were divided into 4  
groups, each group consists of 8 animals: 
 Group (1): Control negative non tumor bearing mice (TB), received 
2ml saline. 
Group (2): EAC control (tumor bearing mice (TB)) received 2 ml 
saline. 
Group (3): EAC (tumor bearing mice (TB)) + colchicines 
(10øg/mice) day after day for 3 weeks after subcutaneous 
implantation of EAC (19). 
Group (4): EAC (tumor bearing mice (TB)) + 5-fluorouracil 
(20mg/kg) was given by intraperitoneal injection on alternate days 
for 3 weeks after subcutaneous implantation of EAC (20). 
The 8 mice from each group were dissected and the ascites fluid 
was collected from peritoneal cavity. The volume was measured by 
taking it in a graduated centrifuge tube. The tumor weight was 
measured by taking the weight of mice before and after collection 
of ascites fluid from peritoneal cavity (21, 22).   
At the end of the study, all mice were sacrificed, blood was 
collected, centrifuged, and plasma was used freshly for estimation 
of plasma glucose (23). The plasma insulin, progesterone and 17β-
estradiol concentration were measured using the insulin ELISA kit 
(Shibayagi Co. Japan) (24-26, respectively), as well as 
transaminases (L-alanine and L-aspartate) (27), alkaline 
phosphatase (ALP) (28). Also, lactate dehydrogenase (LDH) (29), 
TBARS, Pr-SHs and GSH levels in plasma were done by the 
methods described by Buhl and Jackson (30), Uchiyama and 
Mihara (31), Koster, et al., (32) and Chanarin (33), respectively.  
Plasma Superoxide dismutase (SOD) and glutathione peroxidase 
(GPx) activities were carried out Paglia and Valentine (34), 
Marklund and Marklund (35), respectively. Plasma triglyceride, total 
cholesterol and HDL- cholesterol were determined using 
commercially available kits (Asan and Youngdong Pharmaceutical 
Co., Korea) (36-38). Plasma LDL-cholesterol level was calculated 
from Friewald et al (39) formula (LDL-cholesterol = total cholesterol 
ă triglycerides/5 ă HDL-cholesterol). 
Statistical analysis 
All analyses utilized SPSS 15.0 statistical package for Windows 
(SPSS Inc., Chicago, IL) (40). A one-way analysis of variance 
(ANOVA) was employed for comparisons of means of the different 
groups.  A p-value < 0.05 was accepted as statistically significant 
with LSD test as the post ăhoc test. All the results were expressed 
as mean μ SD for eight separate determinations. 
Results 
Injection of colchicine and 5-fluorouracil to mice transplanted with 
carcinoma resulted in a significant decrease in tumour weight 
compared to the group that received subcutaneous implantation of 
EAC (Table 1). The decrease in tumour weight in group of mice 
which injected with 5-fluorouracil (Group 4) was more pronounced 
than colchicine injected mice (Group 3) (p< 0.01).  
 
    Table 1: Effect of Colchicine and 5-fluorouracil on tumor volume and 
              weight 
No. Groups 
                     
Tumor weight
(gm) 
(I)  Normal (Non-tumor bearing mice (NTB))
2ml saline , 0.9% 
0.0 μ 0.00
 
(II) EAC control (tumor bearing mice (TB))
 2 ml saline, 0.9% 
6.2 μ0.30*
(III) Colchicine  
(10øg/kg. b.w. i.p) 
2.7 μ 0.40*
 
(IV
) 
5-Flourouracil     
(20mg/kg b.w. i.p) 
1.60 μ 0.20*
 
 5-Flourouracil was given i.p. day after day at a 20mg/kg b.w. The test colchicine 
was given i.p. daily for 3 weeks.  Values are given as mean μ SD for groups of 
eight animals each.   
 * Significantly different from normal group at p< 0.01. 
 
Subcutaneous implantation of EAC into the right thigh of the lower 
limb of mice resulted in a significant decrease in plasma glucose 
and insulin compared to the normal control group (table 2). 
Intraperitoneal administration of colchicine to mice resulted in a 
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significant increase in plasma glucose and insulin when compared 
to the group that received subcutaneous implantation of EAC (p< 
0.01). However, i.p. injection of 5-fluorouracil resulted in significant 
increase of glucose (p< 0.05) and non-significant increase of 
insulin compared to the group that received subcutaneous 
implantation of EAC.     
  
Table 2: Level of plasma glucose and insulin in normal and experimental groups of mice 
No. Groups
                     
 Glucose
(mg/dl) 
Insulin 
(uIU/ml) 
(I)  Normal (Non-tumor bearing mice (NTB))
2ml saline, 0.9% 
110.73 μ 6.48 13.44 μ 2.05 
 
(II) EAC control (tumor bearing mice (TB))
 2ml saline, 0.9% 
67.83 μ 8.17* 5.61 μ1.27* 
(III) Colchicine 
(10øg/kg. b.w. i.p) 
101.08 μ 7.41@
 
10.19 μ 1.56* 
 
(IV) 5-Flourouracil    
(20mg/kg b.w. i.p) 
77.64 μ 5.40@
 
5.98 μ 1.77  
 
   5-Flourouracil was given i.p. day after day at a 20mg/kg b.w. The test colchicine was given i.p. daily for 3 weeks.  Values are given as mean μ SD for  
groups of eight animals each.   
  * Significantly different from normal group at p< 0.01.   @ Significantly different from control group at p< 0.05. 
 
Tables 3,4 and 5 showed that subcutaneous implantation of EAC 
into the right thigh of the lower limb of mice resulted in a significant 
increase in plasma AST, ALT, ALP, LDH and TBARs as well as 
decrease in plasma Pr-SHs, blood GSH, SOD and GPx compared 
to the normal control group (p< 0.01). Intraperitoneal administration 
of colchicine to mice resulted in a significant decrease in plasma 
AST, ALT, ALP, LDH and TBARs as well as increase in plasma Pr-
SHs (p< 0.01), blood GSH, SOD and GPx (p<.0.05) compared to 
the group that received subcutaneous implantation of EAC (p< 
0.05).  However, injection of 5-fluorouracil to mice resulted in a 
significant decrease in plasma AST, ALT, ALP, LDH and TBARs as 
well as increase in plasma Pr-SHs (p< 0.05) non significant change 
in blood GSH, SOD and GPx  compared to the group that received 
subcutaneous implantation of EAC (p< 0.05).  
 
 
Table 3: Level of plasma alanine transaminase (ALT), aspartate transaminase (AST), alkaline phosphatase (ALP) in serum of normal and      
experimental groups of mice 
No. Groups 
                     
 ALT
(U/L) 
AST 
(U/L) 
ALP 
(U/L) 
(I)  Normal (Non-tumor bearing mice (NTB))
2ml saline, 0.9% 
27.95μ  4.70 32.88 μ 5.22 134.61μ 10.07
(II) EAC control (tumor bearing mice (TB))
 2ml saline, 0.9% 
50.16 μ 6.38* 67.08 μ8.32* 274.36 μ 15.91*
(III) Colchicine (10øg/kg. b.w. i.p) 26.72 μ 5.30* 29.66μ 4.24* 152.48μ 10.95*
(IV) 5-Flourouracil    (20mg/kg b.w. i.p) 35.74μ 6.85@ 38.00 μ 5.00@ 182.22μ 13.94@
 5-Flourouracil was given i.p. day after day at a 20mg/kg b.w. The test colchicine was given i.p. daily for 3 weeks. Values are given as mean μ SD for groups of 
eight animals each.   
 * Significantly different from normal group at p< 0.01.   @ Significantly different from control group at p< 0.05. 
 
Table 4: Levels of plasma lactate dehydrogenase (LDH), lipid peroxides (TBARS) and protein thiols (Pr-SHs) of normal and experimental groups of 
mice 
No. Groups 
                     
 LDH
(U/L) 
TBARS (nmol/ml) Pr-SHs (ømol/l) 
(I)  Normal (Non-tumor bearing mice (NTB))2ml saline, 0.9% 110.37 μ  9.18 40.52μ 3.29 152.16μ 9.42
(II) EAC control (tumor bearing mice (TB)) 2ml saline, 0.9% 246.05μ 14.23* 92.44 μ7.03* 68.90 μ 7.64*
(III) Colchicine (10øg/kg. b.w. i.p) 113.05μ 10.51* 36.11μ 4.60* 129.40μ 11.25*
(IV) 5-Flourouracil    (20mg/kg b.w. i.p) 135.60 μ 18.19@ 52.18μ 6.45@ 85.40μ 9.32@
5-Flourouracil was given i.p. day after day at a 20mg/kg b.w. The test colchicine was given i.p. daily for 3 weeks. Values are given as mean μ SD for groups of 
eight animals each.   
 * Significantly different from normal group at p< 0.01.   @ Significantly different from control group at p< 0.05. 
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Table 5: Level of reduced glutathione (GSH), superoxide dismutase (SOD) and glutathione peroxidase (GPx) in blood of normal and experimental  
groups of mice 
 
No. Groups 
                     
 GSH
(mg%) 
SOD  
(U/g Hb) 
GPx 
(U/g Hb) 
(I)  Normal (Non-tumor bearing mice (NTB))2ml saline, 0.9% 25.46 μ  3.22 62.82μ 3.29 95.74μ 9.42
(II) EAC control (tumor bearing mice (TB)) 2ml saline, 0.9% 14.08μ 2.97* 42.63 μ3.95* 67.90 μ 4.38*
(III) Colchicine (10øg/kg. b.w. i.p) 22.13μ 4.77@ 56.70μ 8.05@ 92.05μ 5.14@
(IV) 5-Flourouracil    (20mg/kg b.w. i.p) 12.41 μ 4.10 43.60μ 5.21  61.05μ 7.33
 
5-Flourouracil was given i.p. day after day at a 20mg/kg b.w. The test colchicine was given i.p. daily for 3 weeks. Values are given as mean μ SD for groups     
of eight animals each.  Activity is expressed as: 50% of inhibition of pyrogallol autooxidation per min for SOD and the obtained values were divided by the 
haemoglobin (Hb) concentration.Values are given as mean μ SD for groups of eight animals each.   
        * Significantly different from normal group at p< 0.01.      @ Significantly different from control group at p< 0.05. 
 
Tables 6 showed that subcutaneous implantation of EAC into the 
right thigh of the lower limb of mice resulted in a significant 
decrease in plasma cholesterol (TC), triglycerides (TG), HDL-C 
and LDL-C compared to the normal control group (p< 0.01).  
Intraperitoneal administration of colchicine to mice resulted in a 
significant increase in plasma TC, TG, HDL-C and LDL-C 
compared to the group that received subcutaneous implantation of 
EAC (p< 0.01).  In addition, injection of 5-fluorouracil to mice 
resulted in a significant increase in plasma TC, TG, HDL-C and 
LDL-C compared to the group that received subcutaneous 
implantation of EAC (p< 0.05).     
  
Table 6: Level of plasma total cholesterol (TC), triglycerides (TG), HDL-C and LDL-C of normal and experimental groups of mice 
 
No. Groups 
                     
TC
(mg/dl) 
TG 
(mg/dl) 
 HDL-C 
 (mg/dl) 
LDL-C
(mg/dl) 
(I)  Normal (Non-tumor bearing mice (NTB)) 2ml 
saline, 0.9% 
124.43 μ  9.61 109.16μ 6.39 34.29μ 5.05 68.31μ 4.32
(II) EAC control (tumor bearing mice (TB))  2ml 
saline, 0.9% 
73.76μ 10.81* 67.24μ5.90* 20.64 μ 3.95* 39.67μ 6.22*
(III) Colchicine (10øg/kg. b.w. i.p) 101.42μ 10.23* 92.35μ 8.67* 31.22μ 5.39 * 51.73μ 3.11*
(IV) 5-Flourouracil    (20mg/kg b.w. i.p) 81.46 μ 6.85@ 59.57μ 6.18@ 25.68μ 4.39@ 43.87@μ 5.33
 
5-Flourouracil was given i.p. day after day at a 20mg/kg b.w. The test colchicine was given i.p. daily for 3 weeks. Values are given as mean μ SD for groups of 
eight animals each. Values are given as mean μ SD for groups of eight animals each.  LDL-C (mg/dl) = TC-HDL-[TG / 5],     
      * Significantly different from normal group at p< 0.01.      @ Significantly different from control group at p< 0.05. 
 
 Tables 7 showed that subcutaneous implantation of EAC into the 
right thigh of the lower limb of mice resulted in a significant 
decrease in plasma estrogen and progesterone compared to the 
normal control group (p< 0.01). Intraperitoneal administration of 
colchicine and 5-fluorouracil to mice resulted in a significant 
increase in plasma 17β-estradiol (p< 0.01) and progesterone 
(p<0.05) compared to the group that received subcutaneous 
implantation of EAC.    
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Table 7: Level of plasma 17β-estradiol and progesterone of normal and experimental groups of mice 
No. Groups 
                     
17β-estradiol 
(pg/ml) 
Progesterone (ng/ml) 
(I)  Normal (Non-tumor bearing mice (NTB)) 2ml 
saline, 0.9% 
12.70 μ  1.35 20.63μ 2.54 
(II) EAC control (tumor bearing mice (TB))  2ml 
saline, 0.9% 
2.54μ 0.39* 12.58μ2.03* 
(III) Colchicine (10øg/kg. b.w. i.p) 9.21μ 3.54* 18.05μ 3.20@ 
(IV) 5-Flourouracil    (20mg/kg b.w. i.p) 10.03 μ 1.76* 14.93μ 3.71@ 
 
5-Flourouracil was given i.p. day after day at a 20mg/kg b.w. The test colchicine was given i.p. daily for 3 weeks. Values are given as mean μ SD for groups 
of eight animals each. Values are given as mean μ SD for groups of eight animals each.  * Significantly different from normal group at p< 0.01.  @ 
Significantly different from control group at p< 0.05. 
 
Discussion  
Colchicine, a heterocyclic alkaloid (41) has been used for centuries 
in acute gout arthritis (42). During the recent decades, it has been 
employed for an increasing number of disorders such as BD, FMF, 
liver cirrhosis, dermatologic disorders and scleroderma (43) and 
free radical generation was found in some of these diseases (44, 
45). 
The present article aimed to study the antitumor activity of 
colchicine, 10øg/mice, day after day for 3 weeks in EAC bearing 
mice compared to 5-Flourouracil 20mg/kg. b.w. a standard 
antitumor drug. Cancer is a pathological state involving 
uncontrolled proliferation of tumor cells. Reduced weight of tumor 
indicated a decrease in abnormal cell divisions, i.e. tumor 
proliferation (46, 47).   
The present results showed that EAC implantation caused fall of 
blood glucose and insulin in EAC control mice. Hypoglycemia was 
proportional to the number of tumor cells inoculated into the host. 
One reason for hypoglycemia could be an augmented consumption 
of glucose by the cells of the tumor (48, 49). Indeed, hypoglycemia 
was most expressed in mice with large tumors, i.e., with the 
highest tumor volume and weight due to transport of glucose 
through the membrane of tumor (50). Facilitated transport of 
glucose is attributed to the changes of the membrane of tumor cells 
(51) and increase of insulin-like (glucose-lowering) substances 
level in the tumor cells, or produces an insulin-like (glucose-
lowering) principle itself. Several authors have described higher 
concentration of insulin-like substances in the plasma of mice with 
some tumors (52, 53). However, we have found a decrease of 
insulin activity in the plasma of EAC control group. 
Supplementation of colchicine and 5-Flourouracil resulted in 
increase glucose and insulin levels compared to EAC control 
group. The antioxidant effect of colchicine was investigated by Das 
et al. (16) which may decrease the rate of glucose and insulin 
transport to the tumor cells. 
 
 
 
 
Liver is considered to be the main organ of drug detoxifying organ, 
some liver marker enzyme levels were measured from serum. 
AST, ALT, ALP, LDH and TBARs levels were increased in EAC 
controlled mice, whereas Pr-SHs, GSH, SOD and GPx levels were 
decreased.  In the present study, subcutaneous implantation of 
EAC into the mice resulted in a significant decrease in blood GSH, 
SOD and GPx as well as plasma TC, TG, HDL-C and LDL-C with a 
significant increase in plasma TBARs compared to the normal 
control group. These results were in agreement with Raju and 
Arockiasamy (54) who reported that the consumption of free amino 
acid for building the proteins of rapidly dividing tumor cells might 
result in the disturbance of the enzyme activity in the liver (55). 
Treatment with colchicine altered liver enzymes level and restored 
them to that of the normal group.   
Alterations of cholesterol metabolism, including increased 
cholesterol synthesis and accumulation of cholesterol esters in 
tumor tissues associated with a decrease of high density 
lipoprotein cholesterol in serum, were previously observed in 
different models of neoplastic cell proliferation including 
haematological malignancies. A number of studies had indicated 
that reactive oxygen species (ROS) are involved in a variety of 
different cellular processes ranging from apoptosis and necrosis to 
cell proliferation and carcinogenesis. In this study; there was a 
significant decrease in levels of GSH, SOD, GPx & Pr-SHs and 
elevation in liver enzymes and MDA levels of EAC control group.  
According to our results, it can be stated that the antioxidant 
activity of colchicine (44, 45) due its structure property, this 
important property may be responsible for its antitumor activity 
against EAC in vivo. The structural requirement considered 
essential for effective radical scavenging by colchicine is the 
presence of P-dimethoxy groups at carbon number 1 and 2 in A 
ring and conjugated double bond. The presence of double bond in 
A ring makes the electrons more delocalized to form quinone 
structure which possesses electron donating properties and is a 
radical target (56) (scheme 1).   
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Scheme 1: Proposal mechanism of colchicine antioxidant activity 
The present work showed that EAC implantation caused fall of 
plasma sex hormones; 17β-estradiol and progesterone as 
compared with normal control mice. EAC bearing mice associated 
with increase receptor population (57, 58) and altered 17β-
estradiol and progesterone levels were brought back to normal by 
colchicine and 5-Flourouracil treatment.  
Therefore, from the present study it can be concluded that 
colchicine showed promising antitumor potential in Ehrlich ascites 
carcinoma bearing albino mice which can be attributed to its 
structure requirements.  
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